Lantheus considers US$7B takeover offer from Curium Pharma

USA—Radiopharmaceutical company Lantheus Holdings is considering a takeover offer from Curium Pharma, with a potential deal valued at approximately US$7 billion, according to recent reports from Bloomberg and Reuters.

The discussions, which could conclude within weeks, reflect the growing investor interest in the rapidly expanding nuclear medicine sector.

Although negotiations are ongoing, neither company has confirmed the transaction.

Lantheus said it does not comment on market speculation, while Curium noted that it continuously evaluates strategic growth opportunities but would not address rumors directly.

The proposed acquisition comes at a time when radiopharmaceuticals are attracting unprecedented attention from investors, healthcare providers, and pharmaceutical manufacturers.

These therapies and diagnostic agents use small amounts of radioactive material to detect and treat diseases, particularly cancer and neurological disorders.

Lantheus expands its radiopharmaceutical footprint

Over the past two years, Lantheus has aggressively expanded its portfolio through acquisitions and product development initiatives.

In early 2025, the company acquired Evergreen Theragnostics in a US$250 million deal, with additional milestone payments that could bring the total to US$752.5 million.

The acquisition strengthened Lantheus’ manufacturing capabilities and expanded its oncology imaging pipeline.

The company also purchased Meilleur Technologies and later acquired imaging assets from Life Molecular Imaging, including the Alzheimer’s PET imaging agent Neuraceq.

More recently, Lantheus reported first-quarter 2026 revenues of US$377.3 million, supported by strong demand for its prostate cancer imaging agent Pylarify, Alzheimer’s imaging product Neuraceq, and ultrasound-enhancing agent Definity.

The company also received FDA approval for PYLARIFY TruVu, a next-generation formulation designed to improve manufacturing efficiency and expand access to imaging across the United States.

In addition, the FDA granted tentative approval for PNT2003, Lantheus’ radioequivalent version of Novartis’ neuroendocrine tumor therapy Lutathera.

Last week, Lantheus also announced new radiodiagnostic data presentations scheduled for the 2026 SNMMI Annual Meeting and the ASCO Annual Meeting, highlighting its continued push into precision oncology imaging.

Nuclear medicine investment surge accelerates

The potential acquisition coincides with major investments across the radiopharmaceutical supply chain.

Earlier this month, TerraPower Isotopes broke ground on a 250,000-square-foot actinium-225 production facility in Philadelphia’s Bellwether District, which the company describes as the world’s largest dedicated Ac-225 manufacturing facility.

Similarly, radioisotope supplier Niowave recently launched construction of a US$75 million facility in Lansing, Michigan, aimed at increasing production of alpha-emitting isotope actinium-225 for cancer therapies.

Meanwhile, Curium itself continues to attract investor confidence. Last year, its majority owner, CapVest, recapitalized the company through a continuation vehicle transaction that also valued Curium at approximately US$7 billion.

Investors involved in the financing cited strong long-term growth expectations for the nuclear medicine market.